دورية أكاديمية
The History of Transcatheter Aortic Valve Implantation (TAVI)-A Personal View Over 25 Years of development.
| العنوان: | The History of Transcatheter Aortic Valve Implantation (TAVI)-A Personal View Over 25 Years of development. |
|---|---|
| المؤلفون: | Figulla HR; Friedrich Schiller University Jena, Jena, Germany. Electronic address: hans.figulla@googlemail.com., Franz M; Friedrich Schiller University Jena, Jena University Hospital, Department of Internal Medicine I, Jena, Germany., Lauten A; Charité-Universitätsmedizin Berlin, University Heart Centre, Department of Cardiology, German Centre for Cardiovascular Research (DZHK), Berlin, Germany. |
| المصدر: | Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2020 Mar; Vol. 21 (3), pp. 398-403. Date of Electronic Publication: 2019 Jun 12. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101238551 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0938 (Electronic) Linking ISSN: 18780938 NLM ISO Abbreviation: Cardiovasc Revasc Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier, c2005- |
| مواضيع طبية MeSH: | Aortic Valve Stenosis*/diagnostic imaging , Aortic Valve Stenosis*/etiology , Aortic Valve Stenosis*/surgery , Heart Valve Prosthesis* , Heart Valve Prosthesis Implantation* , Transcatheter Aortic Valve Replacement*/adverse effects , Transcatheter Aortic Valve Replacement*/methods, Aortic Valve/diagnostic imaging ; Aortic Valve/surgery ; Humans ; Prosthesis Design ; Treatment Outcome |
| مستخلص: | In the early 1990s, the idea of Transcatheter Aortic Valve Implantation (TAVI) emerged from clinicians by the insight that the long-term hemodynamic and clinical results of aortic balloon valvuloplasty to treat aortic stenonosis were not satisfying. Thus, Anderson and Cribier developed the balloon-expandable and Figulla and Laborde the self-expendable TAVI systems. Sceptical views by the surgical colleagues and the industry delayed the rapid development of this disruptive new therapy until 2002, when Alain Cribier demonstrated for the first time the proof of his concept. Bulky devices and paravalvular leakages in patients treated in terms of compassionate care resulted in high mortality rates. From 2005 onwards, the treatment of patients not at highest risk using smoother devices in clinical trials could demonstrate that the technology was equivalent to surgical aortic valve replacement. The transapical access route initiated the heart team approach with the surgical colleagues, however, this access route is presently expiring due to its greater trauma. The need to treat also aortic regurgitation is addressed by the "clipping technology" of JenaValve™. Ongoing clinical trials investigate an extended indication for TAVI at an earlier stage of aortic stenosis, or in reduced ejection fraction, and just demonstrated the safety and efficiency even in low surgical risk patients. (Copyright © 2019. Published by Elsevier Inc.) |
| فهرسة مساهمة: | Keywords: CoreValve™; Edwards Sapien 3; JenaValve™; PARTNER trial; Valvuloplasty |
| تواريخ الأحداث: | Date Created: 20190807 Date Completed: 20220505 Latest Revision: 20220505 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.carrev.2019.05.024 |
| PMID: | 31383557 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1878-0938 |
|---|---|
| DOI: | 10.1016/j.carrev.2019.05.024 |